12,372 trials
Type 2 Diabetes
Primary: Change in HbA1c From Baseline to Week 26 — -0.63; -0.58; -0.84 percentage of hemoglobin
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) — 5.55; -3.24 Units on a scale
Neovascular Age-related Macular Degeneration
Primary: Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — 0.1; 1.0 Letters correctly read
Chronic Renal Failure
Primary: Mean Percent of Successful HD Sessions — 99.9 Percentage of HD Sessions
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale
Advanced NET of GI Origin · Advanced NET of Lung Origin · Neuroendocrine Tumors
Primary: Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment — 90.1; 74.6; 81.2; 49.1 Percent event-free…
Asthma · Wheezing
Primary: Progression to Clinically Significant Lower Respiratory Tract Symptoms — 35; 57 participants — p=0.04
Chemotherapy-induced Nausea and Vomiting
Primary: Delayed Phase Complete Response (CR) Rate — 64.7; 56.6 percentage of participants
Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1 — 160; 163; 156; 178 participants
Psoriasis Vulgaris
Primary: Overall Treatment Preference by Subject's Preference Assessment (SPA) at Week 2 and Association With Baseline Characteristics — 49.5; 52.9; 46.2; 50.5 percentage of…
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) — -1.22; -0.99; -0.75 units on a scale — p=.015
Primary Fibromyalgia
Primary: Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12 — -1.39; -0.95 units on a scale
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
COPD
Primary: Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count — 96.4 Percentage
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants